Mozarin (Escitalopram)

Escitalopram, the active ingredient in Mozarin, is a selective serotonin reuptake inhibitor (SSRI) presented as a oral formulation for oral use. It is used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder in adult patients.

GNH USA supplies Mozarin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Escitalopram acts on serotonergic pathways and is prescribed for several mood‑related conditions.

Major depressive disorder: alleviates depressive symptoms and improves mood. Generalized anxiety disorder: reduces excessive worry and physical tension. Social anxiety disorder: lessens fear of social situations and improves functioning. Panic disorder: decreases frequency and intensity of panic attacks.

Escitalopram may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Headache - Insomnia or somnolence - Dry mouth - Sexual dysfunction - Dizziness

Serious or Rare Side Effects: - Serotonin syndrome (hyperthermia, agitation, neuromuscular abnormalities) - Suicidal thoughts or behavior, especially in young adults - Severe allergic reactions (rash, angioedema, anaphylaxis) - QT interval prolongation - Abnormal bleeding or bruising

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly. - Suicidality assessment: screen for suicidal thoughts, especially during early treatment. - Serotonin syndrome vigilance: watch for signs of hyperthermia, rigidity, or autonomic instability. - Hepatic impairment: adjust use in patients with significant liver disease. - Discontinuation: avoid abrupt cessation; taper under medical supervision. - Concomitant serotonergic agents: assess risk of additive effects. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Escitalopram can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs) within 14 days - Pimozide (risk of QT prolongation) - Linezolid (serotonergic activity) - Tramadol (serotonin syndrome risk) - St. John’s wort (increased serotonergic effect)

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (bleeding risk) - Anticoagulants/antiplatelets (enhanced bleeding) - Other SSRIs or SNRIs (serotonin syndrome potential) - Carbamazepine (reduced escitalopram levels) - Alcohol (may increase CNS depression)